Emergent BioSolutions Inc. revised earnings guidance for the year 2024. For the year, the company expects total revenues of $1,000 million to $1,100 million compared to previous guidance of $900 million to $1,100 million. Net loss of $148 million to $98 million compared to previous guidance of $183 million to $133 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.19 USD | -1.12% | +8.60% | +157.92% |
May. 02 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
May. 02 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+157.92% | 324M | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
-0.78% | 219B | |
+11.88% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- EBS Stock
- News Emergent BioSolutions Inc.
- Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2024